Paper Details

  1. Home
  2. Paper Details

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.

Author: AlvarezLuisa, CaballeríaLlorenç, GuañabensNuria, Martínez de OsabaM Jesus, MonegalAna, ParésAlbert, PerisPilar, PonsFrancesca, RocaMerce, RodésJuan, RosInmaculada

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

This study compared the effects of alendronate and cyclical etidronate on bone mass in patients with primary biliary cirrhosis. The study found that both treatments increased bone mineral density after 2 years, but the increase was significantly higher in patients receiving alendronate. Alendronate was associated with minor or no side effects and did not impair liver function or cholestasis.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Osteopenia increases the morbidity of primary biliary cirrhosis (PBC). In this study, we have compared two bisphosphonates, alendronate and cyclical etidronate, that inhibit osteoclast-mediated bone resorption and have examined their effects on bone mass in patients with this disease. M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1572-0241.2003.07639.x

データ提供：米国国立医学図書館（NLM）

Alendronate: A Powerful Ally Against Osteopenia in Primary Biliary Cirrhosis

Primary biliary cirrhosis (PBC), like a relentless desert wind, can erode bone density, leading to osteopenia. This study, like a meticulous archaeologist unearthing ancient artifacts, explores the effectiveness of two bisphosphonates, alendronate and etidronate, in combating this bone-weakening condition.

The researchers, with the patience of a desert sculptor, meticulously followed 32 women with PBC, randomly assigning them to receive either alendronate or etidronate for 14 days every 3 months. They meticulously monitored bone mineral density, biochemical markers, and any potential adverse effects, like a skilled desert navigator charting a course through a challenging terrain.

The results revealed that both treatments increased bone mineral density, but alendronate, like a sturdy camel, exhibited a significantly greater effect than etidronate. This increase paralleled changes in biochemical markers of bone turnover, indicating alendronate's potent antiresorptive power.

A Strong Defense Against Bone Loss

The study demonstrates the superior efficacy of alendronate in increasing bone mass in patients with PBC, offering a powerful defense against bone loss. It's like discovering a sturdy fortress in the desert, providing protection against the erosion of bone density.

Strengthening Bones and Navigating the Desert of PBC

This research provides valuable information for healthcare professionals and patients navigating the desert of PBC. It highlights the effectiveness of alendronate in combating osteopenia associated with PBC, offering a chance to build strong bones and endure the challenges of this complex disease, like a traveler finding a reliable oasis amidst a harsh landscape.

Dr. Camel's Conclusion

This study highlights the efficacy of alendronate in increasing bone mass in patients with PBC, offering a powerful defense against bone loss. It's like discovering a sturdy fortress in the desert, providing protection against the erosion of bone density.

Date :
  1. Date Completed 2003-11-26
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

14572578

DOI: Digital Object Identifier

10.1111/j.1572-0241.2003.07639.x

Related Literature

Article Analysis
・Side Effects of etidronate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.